Stock IPA IMMUNOPRECISE ANTIBODIES LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News ImmunoPrecise Antibodies Ltd.

Equities

IPA

CA45257F2008

Real-time Estimate Cboe BZX
Other stock markets
 10:36:46 2024-05-09 am EDT 		5-day change 1st Jan Change
1.24 USD -3.13% Intraday chart for ImmunoPrecise Antibodies Ltd. +0.79% -25.73%
Apr. 22 ImmunoPrecise Antibodies Ltd. Announces an Expansion of Its LENSai Platform CI
Apr. 12 ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ImmunoPrecise Antibodies Ltd. Announces an Expansion of Its LENSai Platform
CI
ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments
CI
InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications
BU
IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments
BU
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024
AQ
Transcript : ImmunoPrecise Antibodies Ltd., Q3 2024 Earnings Call, Mar 14, 2024
ImmunoPrecise Antibodies : Q3 2024 Earnings Presentation
PU
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*
BU
IMMUNOPRECISE ANTIBODIES : MANAGEMENT DISCUSSION AND ANALYSIS FOR THE THREE AND NINE MONTHS ENDED JANUARY 31, 2024 - Form 6-K
PU
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024
CI
ImmunoPrecise Antibodies : Q3 2024 Earnings Transcript
PU
IPA's subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology
AQ
IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology
BU
Certain Warrants of ImmunoPrecise Antibodies Ltd. are subject to a Lock-Up Agreement Ending on 6-MAR-2024.
CI
Certain Stock Options of ImmunoPrecise Antibodies Ltd. are subject to a Lock-Up Agreement Ending on 6-MAR-2024.
CI
Certain Common Shares of ImmunoPrecise Antibodies Ltd. are subject to a Lock-Up Agreement Ending on 6-MAR-2024.
CI
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024
BU
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024
AQ
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023
CI
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024*
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IPA Stock
  4. News ImmunoPrecise Antibodies Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW